Catalog3 refs
Survodutide (BI 456906)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy. Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Primary Uses
Obesity without diabetes (14.9% mean weight loss at 46 weeks)
Obesity with Type 2 diabetes (superior to semaglutide)
Sustained weight management
MASH treatment (62% improvement without fibrosis worsening)
Liver fat reduction (63-67% achieved ≥30% reduction)
Type 2 diabetes control (HbA1c reduction up to -1.6%)
Protocol Reference
Dose
0.6mg starting, titrate up to 3.6-6.0mg weekly; MASH: 2.4-4.8mg; Type 2 Diabetes: 0.3-2.7mg
Frequency
Once weekly (same day each week)
Half-life
Approximately 6 days (109-115 hours)
Route
Subcutaneous injection to abdomen (2+ inches from navel) · Subcutaneous injection to upper thigh · Subcutaneous injection to upper arm
Evidence
Extensively Studied
Research Models
Human
Also in Metabolic